Filterable News List

Pittsburgh, Pennsylvania, USA - DataMEDS AI, Inc. (NASDAQ: MEDS) announced the completion of the acquisition of the artificial intelligence cancer diagnostics laboratory business Helomics Corporation from Axe Compute Inc. (NASDAQ: AGPU).

Under the agreement, DataMEDS acquired Helomics for a total purchase value of $1.5 million in common shares and an acquisition note. The transaction includes the Helomics CLIA/CAP-certified clinical laboratory with all equipment, the Predictive Oncology contract research organization central lab services business, and $1.5 million in cash, with no third-party debt.

Transaction Highlights

• Total Purchase Value: $1.5 million paid in common shares and an acquisition note.

• Assets Acquired: Helomics CLIA/CAP-certified clinical lab, equipment, Predictive Oncology CRO business, and $1.5 million in cash.

• Strategic Expansion: DataMEDS enters the oncology and cancer diagnostics market, expanding beyond GLP-1 agonist side effects and Long COVID.

New York, NY, USA. Churchill Capital Corp XIII (Nasdaq: XIIIU) announced that starting September 18, 2026, holders of the units sold in its initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units.Trading DetailsThe separated Class A ordinary shares and warrants will trade on the Nasdaq…

… Read on — Pro Members

New York, NY - September 15, 2026 - Critical Metals Corp. (Nasdaq: CRML) provided an update on its proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) following a favorable court ruling in Australia.

Court Orders and Scheme Meetings

The Supreme Court of Western Australia has granted orders directing European Lithium to convene meetings of its shareholders and optionholders to vote on the proposed schemes of arrangement. The Scheme Booklet has also been registered with the Australian Securities and Investments Commission (ASIC).

Transaction Details

• Acquisition of 100 percent of European Lithium's issued share capital and listed options.
• Consideration to be satisfied by issuing new ordinary shares in Critical Metals Corp.
• Scheme meetings scheduled for Thursday, October 22, 2026, in West Leederville, Western Australia.
• Implementation of the schemes is expected in November 2026, pending securityholder and court approvals.

New York, NY, USA - Market Technology Acquisition Corp (Nasdaq: MTAKU) announced that starting September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units.The separated Class A ordinary shares and warrants will trade on the Nasdaq…

… Read on — Pro Members

La Jolla, California, USA - Three Lions Acquisition Corp. announced that, commencing on or about September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the ordinary shares and warrants included in the units.The separated ordinary shares and warrants are expected to trade on the Nasdaq Global…

… Read on — Pro Members

Santa Monica, California, USA - Catalyst Acquisition Corp. (Nasdaq: CATLU) announced that, commencing September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the Class A ordinary shares and rights included in the units.The separated Class A ordinary shares and rights will trade on the Nasdaq Stock…

… Read on — Pro Members

Hong Kong, HK -- Tianci International, Inc. (NASDAQ: CIIT) announced that it has entered into a Memorandum of Understanding on Strategic Cooperation with BTC Digital Ltd. (NASDAQ: BTCT) for an approximately 3 MW crypto computing project, initiating the phased advancement of the initiative.

The project builds upon a prior strategic cooperation memorandum signed on October 14, 2025, and existing mining-equipment hosting arrangements between the companies. Under the new agreement, CIIT plans to deploy crypto computing equipment in phases to reach an aggregate electrical load of approximately 3 MW within twelve months. BTCT will provide infrastructure and operational support, including sites, power, and equipment deployment.

Transaction Details

• CIIT targets an aggregate electrical load of approximately 3 MW within twelve months.
• BTCT provides sites, power, hosting infrastructure, and operational support.
• CIIT handles equipment procurement, project funding, transportation, insurance, and permits.
• The non-binding MOU has a twelve-month term and allows for separate definitive agreements.

Irvine, California, USA - Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in advanced diabetes management solutions, announced the U.S. Food and Drug Administration (FDA) clearance of Mint, its new patch pump featuring a transformative reusable and disposable architecture. Additionally, the company unveiled 3D Intelligence, its next-generation insulin dosing algorithm, which has been submitted to the FDA via a 510(k) application.

The Mint patch pump does not require recharging, integrates with industry-leading continuous glucose monitors, and enables smartphone control for both iOS and Android users. The full commercial launch in the United States is anticipated to begin in the first quarter of 2027, with expected manufacturing capacity to produce at least 1.5 million disposable units during 2027.

The newly unveiled 3D Intelligence algorithm is designed to offer clinicians three selectable experiences: Original, Optimized, and Conservative. Subject to regulatory clearance, the algorithm is expected to power both iLet 3D and Mint 3D platforms, maximizing user choice in hardware and treatment approach.

Key Highlights

• FDA clearance received for the Mint patch pump architecture.
• Full U.S. commercialization expected in Q1 2027.
• 3D Intelligence algorithm submitted to the FDA through a 510(k) application.
• Updated full year 2026 revenue guidance estimated at approximately $121 million to $126 million.

SAN DIEGO, September 15, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company, announced updated clinical data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations, such as EGFR C797S. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea.

BH-30643 is an investigational, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor. In patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, the treatment demonstrated significant anti-tumor activity and a favorable safety profile.

Key Highlights

• In 40 patients with EGFR C797S-positive resistance, BH-30643 demonstrated an objective response rate of 45% and a disease control rate of 88%.
• At the time of efficacy follow-up, 63% of patients remained on treatment with a median follow-up of 6.9 months.
• Patients had received a median of two prior lines of therapy, including prior osimertinib, chemotherapy, antibody-drug conjugates, and a history of brain metastases.
• Treatment-related dose reductions and discontinuations were low at 9% and 3%, respectively, among patients treated at expansion doses.

Dayton, MN, USA - Forgent Power Solutions, Inc. (NYSE: FPS), a leading designer and manufacturer of electrical distribution equipment, announced its financial results for the fiscal fourth quarter and full year ended June 30, 2026, exceeding the high end of its guidance.

During the fourth quarter, Forgent achieved revenues of $462 million, marking a 94 percent increase year-over-year. The company reported a net income of $66 million and an Adjusted EBITDA of $113 million, up 163 percent from the prior year. Bookings reached a record $1,503 million, driving the all-time high backlog to $3.0 billion.

For the full fiscal year 2026, revenues totaled $1,420 million with a net income of $106 million and Adjusted EBITDA of $323 million. The company also issued robust guidance for fiscal year 2027, projecting revenues between $2,400 million and $2,600 million.

Financial Highlights

• Q4 Revenues: $462 million (up 94% year-over-year)
• Q4 Net Income: $66 million
• Q4 Adjusted EBITDA: $113 million (up 163% year-over-year)
• Full Year 2026 Revenues: $1,420 million (up 89% year-over-year)